| |
 |
ARTICLES 
|
|
| Neuroendocrine differentiation: a prognostic feature of non-small-cell lung cancer? |
| SB Baylin |
|
JCO Oct 1 1989: 1375–1376.
[PDF]
|
 |
| Improvements in fluorouracil chemotherapy? |
| LH Einhorn |
|
JCO Oct 1 1989: 1377–1379.
[PDF]
|
|
| Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer |
| G Bonadonna |
|
JCO Oct 1 1989: 1380–1397.
[PDF]
|
|
|
The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer |
| |
SL Graziano, R Mazid, N Newman, A Tatum, A Oler, JA Mortimer, JJ Gullo, SM DiFino, and AJ Scalzo |
| |
JCO Oct 1 1989: 1398–1406.
[Abstract]
[PDF]
|
|
|
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma |
| |
MA Poon, MJ O'Connell, CG Moertel, HS Wieand, SA Cullinan, LK Everson, JE Krook, JA Mailliard, JA Laurie, and LK Tschetter |
| |
JCO Oct 1 1989: 1407–1418.
[Abstract]
[PDF]
|
|
|
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group [published erratum appears in J Clin Oncol 1990 Jan;8(1):185] |
| |
N Petrelli, HO Douglass, Jr, L Herrera, D Russell, DM Stablein, HW Bruckner, RJ Mayer, R Schinella, MD Green, and FM Muggia |
| |
JCO Oct 1 1989: 1419–1426.
[Abstract]
[PDF]
|
|
|
Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group |
| |
FH Valone, MA Friedman, PS Wittlinger, T Drakes, PD Eisenberg, M Malec, JF Hannigan, and BW Brown, Jr |
| |
JCO Oct 1 1989: 1427–1436.
[Abstract]
[PDF]
|
|
|
Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group |
| |
|
| |
JCO Oct 1 1989: 1437–1446.
[Abstract]
[PDF]
|
|
|
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic |
| |
JA Laurie, CG Moertel, TR Fleming, HS Wieand, JE Leigh, J Rubin, GW McCormack, JB Gerstner, JE Krook, and J Malliard |
| |
JCO Oct 1 1989: 1447–1456.
[Abstract]
[PDF]
|
|
|
Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer |
| |
SW Hansen, S Helweg-Larsen, and W Trojaborg |
| |
JCO Oct 1 1989: 1457–1461.
[Abstract]
[PDF]
|
|
|
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study |
| |
WP McGuire, 3d, J Arseneau, JA Blessing, PJ DiSaia, KD Hatch, FT Given, Jr, NN Teng, and WT Creasman |
| |
JCO Oct 1 1989: 1462–1468.
[Abstract]
[PDF]
|
|
|
High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease |
| |
B Lund, M Hansen, OP Hansen, and HH Hansen |
| |
JCO Oct 1 1989: 1469–1473.
[Abstract]
[PDF]
|
|
|
The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer |
| |
LE Rutqvist, B Cedermark, T Fornander, U Glas, H Johansson, B Nordenskjold, S Rotstein, L Skoog, A Somell, and T Theve |
| |
JCO Oct 1 1989: 1474–1484.
[Abstract]
[PDF]
|
|
|
Spondylectomy for malignant tumors of the spine |
| |
N Sundaresan, GV DiGiacinto, G Krol, and JE Hughes |
| |
JCO Oct 1 1989: 1485–1491.
[Abstract]
[PDF]
|
|
|
Inability of computed tomography appearance of recurrent malignant astrocytoma to predict survival following reoperation |
| |
KE Wallner, JH Galicich, MG Malkin, E Arbit, G Krol, and MK Rosenblum |
| |
JCO Oct 1 1989: 1492–1496.
[Abstract]
[PDF]
|
|
|
Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience |
| |
SM Schultz, LH Einhorn, DJ Conces, Jr, SD Williams, and PJ Loehrer |
| |
JCO Oct 1 1989: 1497–1503.
[Abstract]
[PDF]
|
|
|
Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group |
| |
TA Alvegard, H Sigurdsson, H Mouridsen, O Solheim, B Unsgaard, U Ringborg, O Dahl, AM Nordentoft, C Blomqvist, and A Rydholm |
| |
JCO Oct 1 1989: 1504–1513.
[Abstract]
[PDF]
|
|
|
Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma |
| |
B Barlogie, WS Velasquez, R Alexanian, and F Cabanillas |
| |
JCO Oct 1 1989: 1514–1517.
[Abstract]
[PDF]
|
|
|
A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels |
| |
F Swan, Jr, WS Velasquez, S Tucker, JR Redman, MA Rodriguez, P McLaughlin, FB Hagemeister, and F Cabanillas |
| |
JCO Oct 1 1989: 1518–1527.
[Abstract]
[PDF]
|
|
|
A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings |
| |
JW Karesh, EJ Goldman, K Reck, SE Kelman, EJ Lee, and CA Schiffer |
| |
JCO Oct 1 1989: 1528–1532.
[Abstract]
[PDF]
|
|
|
Response to pentostatin in hairy-cell leukemia refractory to interferon- alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group |
| |
AD Ho, J Thaler, F Mandelli, F Lauria, R Zittoun, R Willemze, G McVie, AM Marmont, O Prummer, and P Stryckmans |
| |
JCO Oct 1 1989: 1533–1538.
[Abstract]
[PDF]
|
|
|
Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study |
| |
B Camitta, B Leventhal, S Lauer, JJ Shuster, S Adair, J Casper, C Civin, M Graham, D Mahoney, and L Munoz |
| |
JCO Oct 1 1989: 1539–1544.
[Abstract]
[PDF]
|
|
|
A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo |
| |
GD Demetri, DR Spriggs, ML Sherman, KA Arthur, K Imamura, and DW Kufe |
| |
JCO Oct 1 1989: 1545–1553.
[Abstract]
[PDF]
|
|
|
Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy |
| |
G Morstyn, L Campbell, G Lieschke, JE Layton, D Maher, M O'Connor, M Green, W Sheridan, M Vincent, and K Alton |
| |
JCO Oct 1 1989: 1554–1562.
[Abstract]
[PDF]
|
|
|
The association between high-dose cytarabine neurotoxicity and renal insufficiency |
| |
LE Damon, R Mass, and CA Linker |
| |
JCO Oct 1 1989: 1563–1568.
[Abstract]
[PDF]
|
|
|
Acanthocytosis associated with myelodysplasia |
| |
DC Doll, AF List, DA Dayhoff, TS Loy, QS Ringenberg, and JW Yarbro |
| |
JCO Oct 1 1989: 1569–1572.
[Abstract]
[PDF]
|
|
|
Hypocholesterolemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteins |
| |
DE Wilson, GR Birchfield, JS Hejazi, JH Ward, and WE Samlowski |
| |
JCO Oct 1 1989: 1573–1577.
[Abstract]
[PDF]
|
|
| Addition of verapamil to overcome drug resistance in multiple myeloma: preliminary clinical observations in 10 patients |
| LH Trumper, AD Ho, G Wulf, and W Hunstein |
|
JCO Oct 1 1989: 1578–1579.
[PDF]
|
|
| Thromboembolic risk of tamoxifen in patients with stage II breast cancer |
| M Levine |
|
JCO Oct 1 1989: 1579–1580.
[PDF]
|
|
| Adverse interactions between cytotoxic drugs and hormonal agents in human breast cancer cells |
| R Clarke and HW van der Berg |
|
JCO Oct 1 1989: 1580–1582.
[PDF]
|
|
| Malignant tumors in patients with human immunodeficiency virus infection: a report of 580 cases |
| U Tirelli, A Carbone, S Monfardini, A Lazzarin, E Alessi, and S Pileri |
|
JCO Oct 1 1989: 1582–1583.
[PDF]
|
|
